Skip to main content

Dr. Herbert C. Conaway JR., M.D.

Internal Medicine (Internal Medicine Physician)

At a glance

In the NPI registry since
2006

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Internal Medicine Physician primary
    NJ license MA56855

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Internal Medicine per capita by county →

Payments from drug and device companies

In 2025, 1 companies reported 6 payments worth $575 in total to this clinician.

By type
Travel and Lodging$450
Food and Beverage$125

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Feb 28, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Feb 28, 2025
Travel and Lodging
travel to Fort Lauderdale, FL · in-kind
$281
Mar 18, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Mar 18, 2025
Travel and Lodging
travel to Fort Lauderdale, FL · in-kind
$140
Mar 31, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Mar 31, 2025
Travel and Lodging
travel to Fort Lauderdale, FL · in-kind
$28.66

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New Jersey →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $219,506 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Ov…
    Amgen Inc.
  • A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
    Eli Lilly and Company · Completed · NCT06045221
  • A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mel…
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
    Boehringer Ingelheim International GmbH
  • A phase 2, parallel-group, double-blind, placebo-controlled study to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight with type 2…
    Eli Lilly and Company
  • A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mel…
    Boehringer Ingelheim International GmbH

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Internal Medicine clinicians in Delran

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 8, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1649387283. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.